Business Context and Reporting Period
This Form 6-K filing by Akari Therapeutics Plc covers the month of July 2023, specifically dated July 19, 2023. The report discloses the appointment of Wendy DiCicco as the Company's interim Chief Financial Officer (CFO).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation rather than financial performance.
Material Changes
The primary material change is the appointment of Wendy DiCicco as interim CFO, effective July 17, 2023. The Company entered into a six-month consulting agreement with Board Advantage LLC, an entity controlled by Ms. DiCicco.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations or risks. It details the compensation package for the new interim CFO, which includes:
- A monthly fee of $32,000.
- A performance bonus of $70,000 upon achievement of certain milestones.
- Reimbursement of certain expenses.
- An option to purchase 5,000,000 ordinary shares, fully vesting on the first anniversary of the grant date.
Ms. DiCicco brings over 25 years of experience in the life sciences industry, including previous interim and permanent CFO roles at Renovacor, FerGene, Inc., Centinel Spine, and Camber Spine.
Key Facts for Investor Verification
- Verify the vesting schedule and strike price of the 5,000,000 share option granted to the interim CFO.
- Confirm the specific milestones required to trigger the $70,000 performance bonus.
- Monitor the duration of the interim CFO arrangement, which is set for a six-month term.
- Review the Company's cash position to ensure it can support the new monthly compensation obligations alongside existing operational costs.